The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

(2022) C. Meurot et al.   Scientific Reports

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

(2021) Matthias von Herrath et al.   Lancet Diabetes & Endocrinology

Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials

(2021) Jonathan J. H. Bray et al.   DIABETES OBESITY & METABOLISM

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH

(2021) Katharina Luise Hupa-Breier et al.   Biomedicines

Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist

(2021) Rayane Miranda Pontes-da-Silva et al.   INTERNATIONAL JOURNAL OF OBESITY

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus

(2021) Valentina Guarnotta et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy

(2021) Lingli Zhou et al.   JCI Insight

Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation

(2020) Ana I. Duarte et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Preventive Effects of Dulaglutide on Disuse Muscle Atrophy Through Inhibition of Inflammation and Apoptosis by Induction of Hsp72 Expression

(2020) Tram Thi Ngoc Nguyen et al.   Frontiers in Pharmacology

Low-dose lixisenatide protects against early-onset nephropathy induced in diabetic rats

(2020) Rania G. Abdel-latif et al.   LIFE SCIENCES

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

Dulaglutide Modulates the Development of Tissue-Infiltrating Th1/Th17 Cells and the Pathogenicity of Encephalitogenic Th1 Cells in the Central Nervous System

(2019) Hsin-Ying Chiou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway

(2019) Zhi Li et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity

(2019) Philip Newsome et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

(2019) Helena W. Rodbard et al.   DIABETES CARE

Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation

(2019) Foteini Moschovaki Filippidou et al.   AMERICAN JOURNAL OF PATHOLOGY

Glucagon-like peptide-1 receptor agonist exendin-4 mitigates lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages

(2019) Canrong Lu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes

(2019) Habib Yaribeygi et al.   LIFE SCIENCES

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

(2018) Daniel J. Drucker   Cell Metabolism

Glucagon-like peptide-1 receptor expression in the human eye

(2018) Josephine B. Hebsgaard et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a Glucagon-Like Peptide-1 Receptor Agonist, Attenuates Development of Cardiac Allograft Vasculopathy in a Murine Heart Transplant Model

(2018) Zhi-Min Wang et al.   TRANSPLANTATION

Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function

(2018) Jordan Rowlands et al.   Frontiers in Endocrinology

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

(2017) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties

(2016) A Langlois et al.   BRITISH JOURNAL OF PHARMACOLOGY

iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy

(2016) Lydia Lynch et al.   Cell Metabolism

The Cardiovascular Biology of Glucagon-like Peptide-1

(2016) Daniel J. Drucker   Cell Metabolism

Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner

(2016) Łukasz Bułdak et al.   Pharmacological Reports

Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice

(2016) Line S. Bisgaard et al.   PLoS One

Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix

(2015) Emma Robinson et al.   BASIC RESEARCH IN CARDIOLOGY

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

(2015) Bernardo Yusta et al.   DIABETES

Exendin-4 attenuates renal tubular injury by decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice

(2015) Serap Sancar-Bas et al.   GROWTH FACTORS

Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study

(2015) Manfredi Rizzo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cardiovascular Actions of Incretin-Based Therapies

(2014) John R. Ussher et al.   CIRCULATION RESEARCH

Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes

(2014) Antonio Ceriello et al.   DIABETES CARE

IL-1 Signaling in Obesity-Induced Hepatic Lipogenesis and Steatosis

(2014) Kimberly A. Negrin et al.   PLoS One

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration

(2013) Y Wang et al.   BRITISH JOURNAL OF PHARMACOLOGY

Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes

(2013) A. Ceriello et al.   DIABETES CARE

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus

(2013) Andrew E. Hogan et al.   DIABETOLOGIA

Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes

(2013) Lan He et al.   Journal of Diabetes Investigation

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes

(2012) Y.-S. Lee et al.   DIABETOLOGIA

Anti-Inflammatory Properties of Exenatide in Human Pancreatic Islets

(2011) S. R. Cechin et al.   CELL TRANSPLANTATION

Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis

(2011) A. E. Hogan et al.   DIABETOLOGIA

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

(2011) R. Kodera et al.   DIABETOLOGIA

Exenatide Exerts a Potent Antiinflammatory Effect

(2011) Ajay Chaudhuri et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4

(2010) M. Arakawa et al.   DIABETES

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

(2010) I. Hadjiyanni et al.   DIABETOLOGIA

Exendin-4 Protects  -Cells From Interleukin-1 -Induced Apoptosis by Interfering With the c-Jun NH2-Terminal Kinase Pathway

(2008) M. Ferdaoussi et al.   DIABETES

Exendin-4 Modulates Diabetes Onset in Nonobese Diabetic Mice

(2007) Irene Hadjiyanni et al.   ENDOCRINOLOGY